The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

A Guernsey resident believes "people's enjoyment in life" is being sacrificed for the financial cost of using a drug that can treat wet age-related macular degeneration (AMD).

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

GLP-1 drugs are associated with a higher risk of “wet” age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...